Optibiotix Health has successfully raised US$1.3 million though a placing of new shares
April 2020 — Optibiotix Health Plc has completed a fundraising to continue the commercialization of its products with corporate and large retail partners, with a particular focus on the company’s SweetBiotix©.
OptiBiotix Health is a life sciences company operating in one of the most progressive areas of biotechnological research. Developing technologies that modulate the human microbiome – the collective genome of the microbes in the body – OptiBiotix identifies and develops microbial strains, compounds and formulations for use in food ingredients, supplements and active compounds that can impact on human physiology, deriving potential health benefits. With an established pipeline of microbiome modulators, the OptiBiotix team is working in the prevention and management of chronic lifestyle diseases including obesity, hypercholesterolemia and lipid profiles and diabetes.
Our role in the transaction
Oaklins Cavendish’s sister firm finnCap, based in the UK, advised Optibiotix Health on its equity fundraising.
Talk to the deal team
Related deals
Mattina Holding has sold a 5% stake in Gens Aurea via accelerated bookbuild
Mattina Holding S.A. (DVC Partners) has sold a 5% stake in Italian company Gens Aurea S.p.A. through an accelerated bookbuild, raising approximately US$69.96 million.
Learn moreVeremark has completed a secondary share sale
Veremark, the global workplace trust company, has completed an employee and early investor secondary share sale, on the London Stock Exchange’s (LSE) Private Securities Market (PSM), valuing the company at over US$133 million in enterprise value. Crowdcube, Europe’s leading private market liquidity platform, managed the transaction.
Learn moreTandem has completed a voluntary public tender offer for the shares of Compagnia dei Caraibi
Tandem S.r.l. has completed a voluntary public tender offer for 25.99% of the shares in Compagnia dei Caraibi S.p.A.
Learn more